Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RANKL Antibody (Danosumab) for Acute Charcot Neuro-osteoarthropathy Remission in Chronic Kidney Disease

NCT05797259 is registered in ClinicalTrials.gov with Post Graduate Institute of Medical Education and Research, Chandigarh as lead sponsor.

NCT NCT05797259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05797259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RANKL Antibody (Danosumab) for Acute Charcot Neuro-osteoarthropathy Remission in Chronic Kidney Disease
Lead sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase
Phase 4
Overall status
Completed
Start date
March 10, 2019
Completion date
March 31, 2023
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

charcot joint of foot